Monocytes are recruited to the arterial wall by MCP-1 and experimental studies, suggested that inhibiting MCP-1 signaling could slow down atherosclerosis progression and atherosclerotic plaque destabilization, which causes cardiovascular events [3,4]. This evidence concerns the gene CCL2 and atherosclerosis.